Recent Updates
Recently added Catalysts
LUCD Positive Sentiment Score: 75/100

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

Key Takeaway: Lucid Diagnostics Inc. has announced a business update conference call and webcast scheduled for November 13, 2024. The call will be led by CEO Lishan Aklog, who will provide insights into the company’s operations and growth strategy, while CFO Dennis McGrath will discuss the third quarter financial results. Lucid is committed to advancing cancer prevention technologies, particularly through their proprietary EsoGuard® test aimed at early detection of esophageal cancer in at-risk patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics is hosting a business update call indicating proactive communication.
  • The focus on cancer prevention aligns with growing medical advancements.
  • The EsoGuard® Esophageal DNA Test is a notable technological achievement.

Full Press Release Details

Conference Call and Webcast at 8:30AM Eastern Time
NEW YORK, Oct. 30, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, October 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2024 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
SOURCE Lucid Diagnostics

21 %

more press release views with

Frequently Asked Questions

When is the Lucid Diagnostics conference call?

The conference call is on Wednesday, October 13, 2024, at 8:30 AM ET.

Who will host the business update call?

Lishan Aklog, M.D., Chairman and CEO, will host the call.

How can I access the webcast?

The webcast is available on Lucid's investor relations section at luciddx.com.

What will be discussed in the call?

They will discuss business updates and third-quarter 2024 financial results.

How long will the conference call replay be available?

The replay will be available for 30 days on their website.

Last updated: Oct 30, 2024